An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib

Clinical trial NCT03952039 · COMPLETED

Trial details

NCT number: NCT03952039
Sponsor: Celgene
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Primary Myelofibrosis Post-Polycythemia Vera Myelofibrosis

Start date: 2019-09-09
Primary completion: 2022-12-15
Enrollment: 202

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.